Revisiting optimal anticoagulation with unfractionated heparin during coronary stent implantation

Area of Science:

• Cardiology
• Interventional Cardiology
• Clinical Trials

Background:

• Percutaneous coronary intervention (PCI) with stent implantation is a common procedure.
• Activated clotting time (ACT) is used to monitor anticoagulation during PCI.
• The relationship between ACT and clinical outcomes in PCI patients requires further investigation.

Purpose of the Study:

• To evaluate the association between peak procedural activated clotting time (ACT) and the risk of ischemic and bleeding complications.
• To determine if ACT independently predicts adverse events in patients undergoing PCI with stenting.

Main Methods:

• Univariate and multivariate analyses were performed on data from 2,280 patients undergoing PCI with stent implantation.
• Patients' peak procedural ACT was measured and analyzed in relation to ischemic and bleeding events.
• Demographic data, including diabetes mellitus prevalence and glycoprotein IIb/IIIa inhibitor use, were recorded.

Main Results:

• The median ACT was 276 seconds. Incidence of ischemic events across ACT quartiles was 6.3%, 7.5%, 8.1%, and 7.1% (p=0.71).
• Incidence of bleeding complications across ACT quartiles was 6.6%, 5.9%, 6.9%, and 7.3% (p=0.81).
• Activated clotting time (ACT) did not independently predict either ischemic or hemorrhagic complications.

Conclusions:

• Peak procedural ACT is not an independent predictor of ischemic or bleeding complications in patients undergoing PCI with stent implantation.
• Current ACT monitoring may not adequately guide anticoagulation to optimize outcomes in this patient population.
• Further research is needed to establish optimal ACT targets for PCI procedures.